SAS Output

10-APR-2021 6:10

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY ADMIN CCADMIN R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac PREV   0 Y 0 Pre-Registration 632 30 16 8 1 0
            632 30 16 8 1 0
 
      1 Y 1 Blinded drug 120 20 11 4 1 0
          2 Blinded drug 36 0 0 0 0 0
          3 Blinded drug 35 0 0 0 0 0
          4 Blinded drug 122 18 11 5 1 0
            313 38 22 9 2 0
 
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) BREAST SXQOL 1 Y 1 Tissue for PD-L1 testing 1239 367 177 84 34 5
            1239 367 177 84 34 5
 
      2 Y 2 Observation 530 151 78 38 14 4
          3 MK-3475 (Pembrolizumab) 540 169 83 39 15 5
            1070 320 161 77 29 9
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol SURV   1 Y 0 Screening 249 53 26 13 1 0
            249 53 26 13 1 0
 
      2 Y 1 Carvedilol 44 6 4 1 0 0
          2 No prophylaxis 48 13 5 3 1 0
          3 Observation 143 32 18 9 4 0
            235 51 27 13 5 0
 
S1600-Bladder,Radical Cystectomy Outcomes Nutrition SXQOL   1 Y 1 Blinded Nutrition Drink 29 24 24 15 3 0
          2 Blinded Nutrition Drink 29 19 19 17 7 1
            58 43 43 32 10 1
 
S1614-HBV in Ca Pts, TAF vs SOC SXQOL   1 T 4 SOC HBV Treatment 2 1 0 0 0 0
            2 1 0 0 0 0
 
S1703-Met Breast, STM-monitoring v Usual Care CCD SXQOL 1 Y 0 Screening 233 109 49 25 10 4
            233 109 49 25 10 4
 
      2 Y 1 Control (Usual Care) 71 41 24 11 5 3
          2 Intervention (STMDDM) 71 39 23 12 3 1
            142 80 47 23 8 4
 
S1714-CIPN Risk Prediction Cohort Study, Taxanes SXQOL   1 Y 1 Observation 821 560 366 183 53 8
            821 560 366 183 53 8
 
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum GU SXQOL 1 Y 0 Induction SST 344 163 98 54 21 4
            344 163 98 54 21 4
 
      2 Y 1 Standard Systemic Therapy Only 113 55 26 17 8 1
          2 SST + Surgery/RT 114 56 26 14 8 1
            227 111 52 31 16 2
 
S1806-Blad, MIBC, ChemoRT +/- Atezolizumab GU SXQOL 1 Y 0 Initial Registration 153 95 49 28 12 3
            153 95 49 28 12 3
 
      2 Y 1 Chemo + RT 72 44 25 13 5 1
          2 Chemo + RT + Atezolizumab 68 43 22 12 5 2
            140 87 47 25 10 3
 
S1820-Rectal, Diet modification to manage GI sx PEOLC SXQOL 1 Y 0 Run-In 65 62 32 19 6 1
            65 62 32 19 6 1
 
      2 Y 1 Diet Modification Coaching 25 25 12 9 5 2
          2 Healthy Living Education 25 24 15 7 2 0
            50 49 27 16 7 2
 
S1823-GCT, Obs. Cohort, miRNA371 PREV   1 Y 1 Observation 132 132 123 86 34 8
            132 132 123 86 34 8
 
S1826-HD, Adv, Age 12+, N+AVD vs BV+AVD LYMPH SXQOL 1 Y 1 Nivolumab + AVD 203 158 92 56 18 3
          2 Brentuximab Vedotin + AVD 202 156 90 54 18 1
            405 314 182 110 36 4
 
S1827-SCLC, MRI Surveillance +/- PCI LUNG SXQOL 1 Y 1 PCI + MRI brain surveillance 16 16 10 5 1 1
          2 MRI brain surveillance 17 17 9 5 1 1
            33 33 19 10 2 2
 
S1904-Breast, Decision making for chemoprevention PREV   1 Y 1 Standard Education Materials 18 18 18 17 7 2
          2 Support Tools + Standard Education Materials 5 5 5 5 3 0
            23 23 23 22 10 2
 
S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP LYMPH SXQOL 1 Y   0 0 0 0 0 0
            0 0 0 0 0 0
 
S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O LEUK SXQOL 1 Y 2 Early V-O 2 2 2 2 1 1
            2 2 2 2 1 1
 
A011801-BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib BREAST SXQOL 1 E   1 1 1 1 1 0
            1 1 1 1 1 0
 
A021502-Colon, Stg III, Chemo +/- Atezol, ATOMIC GI SXQOL 1 E   44 18 12 3 0 0
            44 18 12 3 0 0
 
A021806-Pancreas, Perioperative vs Adjuvant Chemo GI SXQOL 0 E   4 4 3 2 0 0
            4 4 3 2 0 0
 
      1 E   3 3 3 1 0 0
            3 3 3 1 0 0
 
A031102-GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) GU SXQOL 1 E   8 2 1 1 1 0
            8 2 1 1 1 0
 
A031704-RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo GU SXQOL 1 E   59 44 27 13 1 0
            59 44 27 13 1 0
 
      2 E   28 23 15 7 3 0
            28 23 15 7 3 0
 
A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO LUNG SXQOL 1 E   9 9 9 5 2 1
            9 9 9 5 2 1
 
A221602-CINV in HEC patients, Olanza +/- Fosapre SXQOL PREV 1 E   27 18 12 5 1 0
            27 18 12 5 1 0
 
      2 E   16 11 8 3 0 0
            16 11 8 3 0 0
 
ACCL16N1-Guideline Consistent Treatment AYA ALL CCD   1 T   54 0 0 0 0 0
            54 0 0 0 0 0
 
EA1131-Brst, TNBC, Post-op Chemo vs Obs BREAST SXQOL 0 E   44 7 6 1 0 0
            44 7 6 1 0 0
 
      1 E   30 6 5 1 1 0
            30 6 5 1 1 0
 
EA2186-PANC, mets, Gem+Abraxane vs 5-FU+LV+Nal-IRI GI SXQOL 1 E   6 6 6 3 1 0
            6 6 6 3 1 0
 
EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T MELAN SXQOL 1 E   53 6 4 2 0 0
            53 6 4 2 0 0
 
      2 E   19 3 2 0 0 0
            19 3 2 0 0 0
 
EA8143-RCC, HR, Surg +/- Nivolumab (PROSPER) GU SXQOL 0 E   147 45 19 0 0 0
            147 45 19 0 0 0
 
      1 E   153 61 36 19 7 3
            153 61 36 19 7 3
 
EA9161-CLL, untreated, IOV vs IO in younger pts LEUK SXQOL 0 E   117 68 41 24 12 6
            117 68 41 24 12 6
 
      1 E   154 57 31 15 5 0
            154 57 31 15 5 0
 
MA39-BREAST, Node-Pos, Reg RT vs No Reg RT BREAST SXQOL 1 E   4 3 2 2 1 0
            4 3 2 2 1 0
 
      2 E   3 2 1 1 0 0
            3 2 1 1 0 0
 
NRGBR004-BREAST, Met HER2+, Pac+Tras+Pert +/- Atezo BREAST SXQOL 1 E   7 4 2 1 0 0
            7 4 2 1 0 0
 
      2 E   4 2 1 1 0 0
            4 2 1 1 0 0
 
NRGCC003-SCLC, PCI or HA-PCI LUNG SXQOL 1 E   4 0 0 0 0 0
            4 0 0 0 0 0
 
      2 E   4 0 0 0 0 0
            4 0 0 0 0 0
 
NRGGU005-PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT GU SXQOL 1 E   6 5 4 1 0 0
            6 5 4 1 0 0
 
NRGGU008-Pros,Node+, Abiraterone acetate + Apalutamide GU SXQOL 1 E   3 3 2 1 1 0
            3 3 2 1 1 0
 
NRGLU002-LUNG, Limited Met NSCLC, MST vs LCT + MST LUNG SXQOL 1 E   2 1 1 1 0 0
            2 1 1 1 0 0
 
A011401-Breast, adj, Stage II/III HER2-, weight loss BREAST SXQOL 1 E   333 33 18 11 0 0
            333 33 18 11 0 0
 
      2 E   312 33 19 11 0 0
            312 33 19 11 0 0
 
      3 E   83 83 83 73 15 2
            83 83 83 73 15 2
 
A021602-PANC, Adv PNET Blinded Cabozantinib v Placebo GI SXQOL 1 E   10 4 2 0 0 0
            10 4 2 0 0 0
 
A031501-Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs GU SXQOL 0 E   93 31 11 3 1 1
            93 31 11 3 1 1
 
      1 E   85 24 8 3 2 1
            85 24 8 3 2 1
 
A031801-GU, mRCC, Cabozantinib +/- Radium-223 GU SXQOL 1 E   2 2 2 0 0 0
            2 2 2 0 0 0
 
A211102-Breast, Atypia via RPFNA, Metformin v Placebo PREV   0 E   6 0 0 0 0 0
            6 0 0 0 0 0
 
      1 E   3 0 0 0 0 0
            3 0 0 0 0 0
 
      2 E   1 0 0 0 0 0
            1 0 0 0 0 0
 
A211601-Breast, Stg II-III, Aspirin PREV   1 E   2 0 0 0 0 0
            2 0 0 0 0 0
 
A221505-Brst, Hypofractionated Post Mast Rad SXQOL   1 E   23 7 3 2 0 0
            23 7 3 2 0 0
 
A221702-BREAST, SLN/ALND +/- ARM SXQOL   1 E   15 7 0 0 0 0
            15 7 0 0 0 0
 
A221805-Colorectal, Duloxetine for Oxaliplatin CIPN SXQOL   1 E   2 2 1 1 1 0
            2 2 1 1 1 0
 
A231601C-CCD, OPTI-Surg in older cancer patients CCD   1 E   1 1 1 0 0 0
            1 1 1 0 0 0
 
A231602C-Blood Cancer, Assess Financial Difficulty CCD   1 T   4 4 0 0 0 0
            4 4 0 0 0 0
 
AGCT1532-Inter/Poor Met GCTs, Accel v Std BEP Chemo OTHER SXQOL 1 T   1 0 0 0 0 0
            1 0 0 0 0 0
 
E1Q11-EROS: Reproductive Health in Cancer Survivors SURV SXQOL 1 E   23 0 0 0 0 0
            23 0 0 0 0 0
 
EA2185-Impact of Panc Cyst Surveillance PREV SXQOL 1 E   1 1 1 1 0 0
            1 1 1 1 0 0
 
EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT GU SXQOL 1 E   7 2 1 1 0 0
            7 2 1 1 0 0
 
EAA173-MYEL, SMM, Rd +/- Daratumumab MMYEL SXQOL 0 E   26 19 8 4 4 1
            26 19 8 4 4 1
 
      1 E   13 8 4 1 1 1
            13 8 4 1 1 1
 
EAQ171CD-Smoke Free Support Study 2.0 CCD   0 E   1 0 0 0 0 0
            1 0 0 0 0 0
 
      1 E   1 0 0 0 0 0
            1 0 0 0 0 0
 
EAZ171-Breast, Stg I-III, TIPN Docetaxel/Paclitaxel SXQOL   1 E   3 3 2 2 0 0
            3 3 2 2 0 0
 
G0263-Cerv, Stg I/IIA, adjv RT vs chemoRT OTHER SXQOL 1 E   1 0 0 0 0 0
            1 0 0 0 0 0
 
NHLBIMDS-LEUK, National MDS Study CCD   1 E   111 35 25 11 5 2
            111 35 25 11 5 2
 
NRGBN003-Mening, Grd II, Observation vs Irradiation OTHER SXQOL 1 E   5 0 0 0 0 0
            5 0 0 0 0 0
 
      2 E   3 0 0 0 0 0
            3 0 0 0 0 0
 
NRGCC007-CCD, Increased Dose of SCP in Pros Survivors CCD   0 E   10 10 10 5 2 0
            10 10 10 5 2 0
 
      1 E   10 10 10 5 2 0
            10 10 10 5 2 0
 
NRGGI004-Colorectal, Stg IV, dMMR Immuno-Therapy GI SXQOL 1 T   14 1 0 0 0 0
            14 1 0 0 0 0
 
NRGGY005-OVAR, Cedir vs Olaparib vs C+O vs Std of Care OTHER SXQOL 1 E   4 0 0 0 0 0
            4 0 0 0 0 0
 
NRGHN001-Nasopharyngeal , Indiviual Tx EBV OTHER SXQOL 1 E   9 0 0 0 0 0
            9 0 0 0 0 0
 
      2 E   8 0 0 0 0 0
            8 0 0 0 0 0
 
      3 E   7 0 0 0 0 0
            7 0 0 0 0 0
 
NRGHN004-HN, Adv, RT+Durvalumab vs RT+Cetuximab OTHER SXQOL 1 E   6 4 1 0 0 0
            6 4 1 0 0 0
 
      2 E   6 4 1 0 0 0
            6 4 1 0 0 0
 
NRGHN005-HN, early stg P16-pos, randomize de-intensifi OTHER SXQOL 1 E   4 2 1 1 1 0
            4 2 1 1 1 0
 
NRGLU005-LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo LUNG SXQOL 1 E   1 0 0 0 0 0
            1 0 0 0 0 0
 
R0724-Cervical, Chem+RT +/- Adj. Chemo OTHER SXQOL 1 E   1 0 0 0 0 0
            1 0 0 0 0 0
 
R1008-HN, High-Risk Salivary, Adj RT+Chemo vs RT OTHER SXQOL 1 E   1 1 1 0 0 0
            1 1 1 0 0 0
 
R1216-HN, Adv,Cis vs Dtx vs Dtx+Cetux OTHER SXQOL 1 E   4 1 0 0 0 0
            4 1 0 0 0 0
 
      2 E   3 1 0 0 0 0
            3 1 0 0 0 0
 

10-APR-2021 6:10

Cancer Coltrol Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Admin CCAdmin Registration/Phase Open Date
S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP LYMPH SXQOL 1 Randomization 19-Mar-21